Alemtuzumab (Campath-1H) has been widely used for T-cell depletion following both conventional and reduced-intensity conditioning allografts. We studied the impact of alemtuzumab used in vivo and in vitro on infections, immune reconstitution, and allograft outcome. The use of alemtuzumab in vivo following reduced-intensity conditioning and unrelated donor conventional transplantation was associated with durable engraftment and significant reduction in graft-versus-host disease (GVHD) but at t...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
If you are the owner of this record, you can report an update to it here: Report update to this record